Hansoh Pharmaceutical Group Co. Ltd. has announced that their self-developed B7-H4-targeted antibody-drug conjugate, HS-20089, has been granted Breakthrough-Therapy-Designated Drug status by the National Medical Products Administration (NMPA) of China. This designation is for the proposed treatment of platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer patients. HS-20089, which utilizes a topoisomerase inhibitor payload, is currently undergoing multiple clinical trials in China, with the highest research stage being Phase III. The approval marks a significant step forward in the development of this promising therapy for gynecological tumors.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。